Medtech entrepreneur Lusia Guthrie joins BioMelbourne Network board
BioMelbourne Network has announced the appointment of Lusia Guthrie to its board of directors. With over 35 years in pharmaceutical and bioscience industries, Guthrie is an experienced executive and medtech entrepreneur, with strong leadership skills and international industry networks.
Guthrie started her career as a medical laboratory scientist before joining the manufacturing division of pharmaceutical company FH Faulding & Co. She then went on to co-found medical technology innovation company LBT Innovations, where she served as chief executive officer and managing director before retiring late last year. She acted as interim CEO for BioMelbourne Network earlier this year.
Now in a new chapter of her career, Guthrie is pursuing board directorship as a means of sharing her knowledge, experiences and networks. She has particular experience and ongoing interest in the development and commercialisation of new healthcare products that embrace automation, robotics, machine learning and artificial intelligence.
BioMelbourne Network is an industry-led association for organisations engaged in biotechnology, medical technology and health innovation in the state of Victoria.
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
